TAK-243 clinical trials
Also written MLN7243 and TAK-243.
How each study uses TAK-243 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TAK-243 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
National Cancer Institute (NCI) (2) · Millennium Pharmaceuticals, Inc. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test TAK-243.
- Apr 2027Studying TAK-243 in Patients With Advanced CancerPhase 1 · National Cancer Institute (NCI)
- Oct 2027TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased BlastsPhase 1 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses TAK-243 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Studying TAK-243 in Patients With Advanced CancerRecruitingPhase 1National Cancer Institute (NCI)NCT06223542Written as UAE Inhibitor TAK-243How we know
- TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased BlastsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03816319Written as UAE Inhibitor TAK-243How we know
- A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid TumorsTerminatedPhase 1Millennium Pharmaceuticals, Inc.NCT02045095Written as MLN7243How we know
Codes
What other systems call TAK-243 · ClinicalTrials.gg INT000782
- MeSH (NLM) C000622638TAK-243Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) V9GGV0YCDITAK-243Confirmed FDA, NLM, Wikidata
- Wikidata Q27896185tak-243Confirmed FDA, NLM, Wikidata
- NCI Thesaurus C113788UAE Inhibitor TAK-243One source FDA
- DrugBank DB15013One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000622638 | TAK-243 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | V9GGV0YCDI | TAK-243 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27896185 | tak-243 | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C113788 | UAE Inhibitor TAK-243 | One source FDA |
| DrugBank | DB15013 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.